Skip to main content
Premium Trial:

Request an Annual Quote

Congressional Committee Approves $2B Increase in NIH Funding

NEW YORK (GenomeWeb) — Congress on Friday night approved an appropriations package that includes a $2 billion boost in fiscal year 2019 funding for the National Institutes of Health to $39.1 billion.

The bipartisan bill — agreed upon by a joint House and Senate conference committee — would increase the NIH's budget by 5.4 percent over its current funding level, matching the increase proposed by the Senate Labor, Health and Human Services, and Education appropriations subcommittee last month.

It specifically calls for an additional $425 million for Alzheimer's disease research for a total of $2.34 billion; $429.4 million for the BRAIN initiative, a $29 million increase; and $376 million for the All of Us precision medicine study, $86 million more than in FY 2018.

The bill "includes the fourth consecutive funding increase for the National Institutes of Health, which will pave the way for new medical breakthroughs and lower healthcare costs over the long term," Senator Roy Blunt (R-MO), chairman of the Labor, Health and Human Services, Education, and Related Agencies Appropriations Subcommittee, said in a statement. "We are on track, for the first time in 22 years, to get the Labor-HHS bill to the president's desk by the end of the fiscal year."

The legislation will next be voted on by the full House and Senate.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more